- Company on track to deliver five Investigational New Drug (IND) applications as part of '5 by 5' solid tumor strategy 18 months ahead of original target
- Nomination of ZW209, a novel trispecific T cell engager, as fifth development candidate in the Company's solid tumor portfolio
- Expansion into autoimmune and inflammatory diseases (AIID) and hematology oncology leverages the Company's clinically validated Azymetric technology platform and expertise in multispecific therapeutics
- ZW1528, the Company's first development candidate in AIID, demonstrates dual blockade of two complementary pathways of respiratory inflammation and offers potential benefit in mixed-type chronic obstructive pulmonary disease (COPD)
- In-person and virtual R&D Day featuring Zymeworks research leadership and key opinion leaders to be held today at 8:30 am Eastern Standard Time (EST)
VANCOUVER, British Columbia, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced highlights from its R&D Day reviewing the Company's development progress on its wholly-owned pipeline assets and expansion into new therapeutic areas in hematological cancers and autoimmune and inflammatory diseases (AIID).
